Arcus Biosciences is leaning hard into a promising kidney cancer drug after trial results suggest it could stand out against rivals, with more readouts on the way. The big question is whether upcoming studies and regulators keep cooperating before competitors and side effects narrow the path forward.Read more
Key Takeaways Lead asset casdatifan and a robust late-stage pipeline position Arcus for rapid market share gains and reduced dependency on any single product. Strong financial backing and strategic partnerships enable accelerated development and sustained innovation, supporting superior margins and future revenue streams.Read more
Key Takeaways Dependency on partnerships and a concentrated pipeline exposes the company to funding disruptions, competitive threats, and regulatory setbacks impacting future earnings and cash flow stability. Pricing pressures, payer focus on generics, and macroeconomic challenges may limit revenue growth and hinder sustainable profitability despite a promising pipeline and expedited regulatory pathways.Read more
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC ; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
